Forte Biosciences (FBRX) Preferred Stock Liabilities (2016 - 2020)
Forte Biosciences (FBRX) posted quarterly Preferred Stock Liabilities of $10.5 million for Q1 2020, little changed year-over-year from $10.5 million in Q2 2019, and little changed quarter-over-quarter from $10.5 million in Q4 2019.
Forte Biosciences (FBRX) Preferred Stock Liabilities (2016 - 2020) Analysis & Trends
Forte Biosciences (FBRX) has reported Preferred Stock Liabilities for 5 consecutive years, with $10.5 million the latest figure, recorded in Q1 2020.
- In Q1 2020, Preferred Stock Liabilities changed 0.0% year-over-year to $10.5 million; the TTM figure through Mar 2020 stood at $10.5 million (changed 0.0% YoY), while the FY2019 annual figure was $10.5 million, up 85.81% from the prior year.
- Preferred Stock Liabilities held at $10.5 million in Q1 2020 per FBRX's latest filing, from $10.5 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $131.4 million in Q4 2016 and bottomed at $5.7 million in Q4 2018.
- Historically, Preferred Stock Liabilities has averaged $40.1 million across 5 years, with a median of $10.5 million in 2019.
- Annual changes were most pronounced in 2019 — Preferred Stock Liabilities surged 85.81% — and 2020, when it changed 0.0%.
- Forte Biosciences' Preferred Stock Liabilities stood at $131.4 million in 2016, then changed by 0.0% to $131.4 million in 2017, then plunged by 95.69% to $5.7 million in 2018, then soared by 85.81% to $10.5 million in 2019, then changed by 0.0% to $10.5 million in 2020.
- Business Quant data shows FBRX's Preferred Stock Liabilities at $10.5 million in Q1 2020, $10.5 million in Q4 2019, and $10.5 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 10.52 Mn |
| Dec 31, 2019 | 10.52 Mn |
| Sep 30, 2019 | 10.52 Mn |
| Jun 30, 2019 | 10.52 Mn |
| Mar 31, 2019 | 10.52 Mn |
| Dec 31, 2018 | 5.66 Mn |
| Mar 31, 2017 | 131.41 Mn |
| Dec 31, 2016 | 131.41 Mn |